Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tablet shows promise for chronic hives in small study

NCT ID NCT07611032

Symptom relief Sponsor: OmniSolutions Laboratory Holdings Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tested a daily tablet called NatureU Histra Disslove in 19 adults with chronic hives. Participants took one tablet before a main meal for 28 days. The study measured how well the tablet controlled hives, reduced symptoms, and improved quality of life. Results showed changes in hive control and activity scores from the start to the end of the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Oct 2024

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who signed informed consent before the study and understood the study content, procedures, and possible adverse reactions. 2. Adults diagnosed with chronic urticaria by a dermatologist based on clinical symptoms and medical history. 3. Age 18 to 65 years. 4. Participants with typical wheals with itching and/or angioedema symptoms of chronic urticaria and either a Urticaria Activity Score 7 of at least 7 or a Urticaria Control Test score below 12. 5. Participants willing to maintain normal healthy routines during the study, avoid alcohol, and avoid foods likely to trigger allergic reactions. Exclusion Criteria: 1. Severe internal organ disease, including heart disease, kidney disease, or other serious disease that could affect product metabolism. 2. Known allergy or intolerance to any ingredient of the study product. 3. Other skin disease or systemic disease that could affect urticaria manifestations. 4. Participation in another clinical trial or use of prohibited drug treatment. 5. Heavy smoking, alcohol abuse, or other lifestyle factors that could affect study results. 6. Severe psychological disorder or cognitive impairment that could affect compliance. 7. Inability to follow study dietary restrictions or requirements because of religious or personal reasons. 8. Abnormal blood routine, liver function, kidney function, or other laboratory test results outside the normal range. 9. Population for whom the product was contraindicated, including minors, participants planning pregnancy, pregnant or lactating participants, participants with liver or kidney disease history, and participants taking long-term medication. 10. Any other factor judged by the investigator to make participation inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angioedema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angioedema chronic urticaria urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angioedema Chronic urticaria Urticaria

Contacts and locations

Locations

  • Dao County People's Hospital

    Yongzhou, Hunan, 425300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.